Changing the Paradigm of Cancer Screening, Prevention, and Treatment

Mohan Doss

Abstract
The war on cancer has been fought during the past several decades primarily based on the somatic mutation model of cancer. This has resulted in the emphasis on cancer screening and elimination of any detected cancerous/precancerous cells as the primary method of cancer prevention. This approach has reduced mortality from some cancers, but age-adjusted cancer mortality rates continue to be high. The lack of significant progress in reducing cancer mortality rates may be indicative of a fundamental flaw in the cancer model used. An alternative model of cancer is the immune suppression model of cancer based on the tremendous increase in cancers when the immune system is suppressed. According to this model, the key carcinogenic event is the suppression of the immune system which enables the already existing covert cancers to grow uncontrollably, causing cancer. Hence, cancer screening would consist of identifying those with weak immune system response. The primary mode of cancer prevention and treatment would be boosting of the immune system, for example, through exercise, infection, and low-dose radiation, as they are all known to enhance immune system response and reduce cancers. There is sufficient evidence to justify clinical trials of this approach for cancer screening, prevention, and treatment.

Keywords
cancer screening, cancer prevention, cancer treatment, exercise, infection, low-dose radiation

Introduction
The United States declared a war on cancer with the passage and signing of the National Cancer Act of 1971 and has devoted considerable resources to conquering cancer. Global efforts against cancer have also increased tremendously during the past several decades.1 Many breakthroughs have been made in understanding the nature of cancer,2,3 and there have been major improvements in the techniques of cancer screening, prevention, diagnosis, and treatment over the years.4 However, age-adjusted cancer mortality rates continue to remain high at approximately 170 per 100 000 (Figure 1).5

The lack of significant progress in the cancer field has been acknowledged in recent reviews with statements such as “the current paradigm is immersed in crisis,”6 “the battle has not yet been won, despite a substantial investment in resources,”7 and “the war has not been won.”8 Although there are suggestions to continue on the present course with refinements,9 a major change in the cancer paradigm has also been recommended.6 The purpose of this review is to discuss the current cancer paradigm; identify some of the problems with the present approach to cancer screening, prevention, and treatment; and suggest a new approach for dealing with cancer based on an alternative paradigm.

Current Paradigm of Cancer Screening, Prevention, and Treatment
The somatic mutation model of cancer has been the prevailing paradigm in the cancer field for many decades.9 The transformation of a normal cell to a cancer cell through mutations is considered to be the key event in the carcinogenic process and is in fact generally referred to as carcinogenesis. This transformation has been the subject of intense study with many hallmarks of cancer being identified.2,3 The recently reported positive correlation between lifetime risk for 33 specific types of cancers and the number of stem cell divisions in the corresponding tissues10 appears to lend further support to the idea that cancer is the result of “bad luck,” that is, accumulation of random mutations.

1 Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA, USA

Corresponding Author:
Mohan Doss, Diagnostic Imaging, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Email mohan.doss@fccc.edu
The results from the current approach to cancer have been disappointing. Cancer screening has not been effective in reducing overall cancer mortality, and age-adjusted cancer mortality rates have remained relatively flat in the United States during the past 50 years (Figure 2).

Though there has been some reduction in these rates since the early 1990s, much of the reduction may be related to the decrease in smoking that began in the 1960s following the start of the smoking cessation campaign (Figure 3).

An analysis has suggested that without reductions in smoking, there would have been virtually no decrease in overall cancer mortality in either men or women since the early 1990s. Considering the vastly improved technologies for cancer screening, prevention, detection, and treatment that exist today compared to decades ago, the absence of major progress in cancer mortality rates (when the cancer reduction due to reduced smoking is excluded from consideration) indicates there may be a fundamental flaw in the current approach to cancer based on the somatic mutation model of cancer.

**Problems With the Somatic Mutation Model of Cancer**

There are indeed many reasons why the somatic mutation model of cancer is not valid. Some of the reasons will be discussed here. Figure 4 shows accumulated mutations in spleen of mice as a function of age.

The maximum accumulation of mutations is seen to occur in the early period of growth between conception and maturity when cells would be dividing at high rates and so would be most vulnerable to mutations, but lymphoma rates are at the lowest levels during this period contradicting the somatic mutation model of cancer. For humans, although mutations would be accumulating at high rates during childhood and adolescence, cancer rates are very low during these periods.

An autopsy study has shown that the percentage of patients having cancer cells in their bodies remain more or less unchanged from ages near 50 to older ages (Figure 6), whereas cancer mortality rate increases by more than an order of magnitude between these age ranges, again contradicting the somatic mutation model of cancer. Autopsy studies have shown that almost everyone has covert cancers, that is, precancerous cells or cancerous cells, but lifetime risk of being diagnosed with cancer is about 30% worldwide indicating that cancerous mutations do not imply cancer. Even for newborns, it is estimated that 1 in 5 may have covert premalignant cancer, but cancer rate in children younger than 15 is more than 100 times lower. Thus, cancerous mutations do not imply cancer. In a recent study that examined a small area of skin, a heavy burden of mutations was observed in normal skin cells at a level similar to that seen in many cancers, but the patients did not have skin cancer. Although many carcinogens are mutagens, there are some carcinogens that are not mutagens, for example, alcohol, indicating that some factor other than mutations is causing the cancers. Also, there are...
some mutagens that are not carcinogens, for example, sodium azide,\textsuperscript{38} indicating that mutations do not imply cancer. Another feature of cancers that contradicts the mutation model of cancer is Peto’s paradox—Cancer incidence does not scale with body size across species.\textsuperscript{39} The observed spontaneous regression of tumors for several types of cancers\textsuperscript{40} also contradicts the somatic mutation mode of cancer. Finally, using the somatic mutation model of cancer, the reported increase in DNA damage from even 5 minutes of strenuous exercise\textsuperscript{41} would imply an increased risk of cancer from regular exercise. The observed reduction of cancer mortality with exercise\textsuperscript{42} is completely contradictory to this prediction.

**Immune Suppression Model of Cancer**

An alternative model of cancer is the immune suppression model of cancer, based on the well-known tremendous increase in cancers in patients with organ transplant and patients with HIV/AIDS in whom the immune system is suppressed (Figures 7 and 8).\textsuperscript{43,44} In this model of cancer, a normal cell, with the accumulation of mutations, can become a cancer cell. However, the immune system would prevent the uncontrolled growth of cancer cells by eliminating them or keeping them under control, resulting in covert cancer.\textsuperscript{45} When the immune system is suppressed, for example, due to aging (Figure 9),\textsuperscript{46} the covert cancers would grow uncontrollably to overt cancers. There is indeed a large amount of supportive evidence for the immune suppression model of cancer in the form of increased cancer risk observed with the weakening of the immune system and decreased cancer risk observed with the enhancement of the immune system.\textsuperscript{47} Children have the strongest immune system, and aging reduces immune system response (Figure 9)\textsuperscript{46} explaining qualitatively the well-known age-dependent increase in cancer risk (Figure 5).\textsuperscript{33}
Females have stronger immune system than males and have lower risk of cancer compared to males. Allergy sufferers have overactive immune system and have lower risk of cancer. Breastfeeding enhances the immune system in infants, and it reduces childhood leukemias. Exercise and infections enhance the immune system and they both reduce cancers. High-dose radiation, cigarettes, and alcohol suppress the immune system and they all increase cancer risk. Low-dose radiation stimulates the immune system (Figure 10), and reduced cancers have been observed in cohorts that have been exposed incidentally or accidentally to low-dose radiation (Figure 11).

All of this evidence supports the immune suppression model of cancer. However, it is indeed possible for cancers to develop in spite of the fully functioning immune system. As cancerous mutations develop, the immune system would keep the cancerous and precancerous cells under check and in equilibrium. During this equilibrium phase, cancer cells would be undergoing Darwinian evolution and phenotypes of cancer cells that evade the immune system may develop. Such cancer cells would be able to escape the control of the immune system and grow uncontrollably, causing cancer. However,
considering the tremendous decrease in overall cancer mortality rates when the immune system is boosted, and the effectiveness of low-dose radiation cancer treatments which boost the immune system, the immune system evading cancers may not be a significant part of the cancer mix, and the suppression of the immune system is likely to be the primary cause of most cancers.

Cancer Screening, Prevention, and Treatment Under the Immune Suppression Model of Cancer

Cancer Screening
Since suppression of the immune system is the primary cause of cancers, cancer screening should consist of identifying those that have weak immune system response, as they would be the most susceptible to developing clinical cancers. Both innate and adaptive immune systems work cooperatively in
eliminating cancer cells and so it would be useful to quantify both of these immune responses. The immune system responses may be assessed, for example, by challenging peripheral blood mononuclear cells with various agents and assaying immune system-related cytokines. In addition, at the time of any routine immunizations, blood samples can be collected prior to and a few weeks after the immunizations and assayed for the immune system response to the vaccinations. Those found to have weak responses in these assessments should be given interventions such as exercise, infection, and low-dose radiation to elevate their immune system responses, and the effectiveness of the interventions should be confirmed by further assays. Since these interventions would not have any major adverse side effects but would improve health in other aspects, overdiagnosis and overtreatment would not be of as much concern. Clinical trials are needed to assess the effectiveness of this approach to cancer screening.

**Prevention of Cancer**

Since suppression of the immune system is the primary cause of cancers, the primary method of cancer prevention would be to boost the immune system. This can be achieved, for example, via exercise, infection, and low-dose ionizing radiation since they are all known to boost the immune system. However, there are some practical issues in utilizing these interventions.

Though it is well known that exercise improves overall health and is recommended for the general population, a large segment of the population does not engage in much physical activity. Improving compliance with the exercise prescription in the population would be helpful in reducing cancers. The current campaigns for exercise do not emphasize the cancer preventive effect of exercise, and this beneficial effect of exercise is not well known to the public. Modifying the advertising campaign message and stressing the cancer preventive effect of regular exercise may result in better compliance with exercise recommendations.

Stimulation of the immune system through daycare infections in infants is known to reduce the risk of childhood leukemias. For adults also, a history of fevers due to infections has been associated with reduced cancer risk later in life. Whether similar cancer preventive effect may be attained by stimulating the immune systems through vaccinations should be studied.

The use of low-dose radiation for boosting the body’s defenses and preventing cancers should be explored in clinical trials since many population groups that were exposed to low-dose radiation were found to have significantly reduced cancers, as noted earlier (Figure 11). One difficulty with such use of low-dose radiation is that the observed cancer preventive effect of low-dose radiation is not well known. Since ionizing radiation is known to cause DNA damage and mutations, even a small amount of radiation is presumed to increase cancer risk, based on the invalid somatic mutation model of cancer. However, low-dose radiation would also boost the defenses in the body, such as antioxidants and DNA repair enzymes, and so would reduce the occurrence of mutations in the subsequent period, with the final result being reduced DNA damage and mutations following low-dose radiation exposures. This has been observed in studies with *Drosophila melanogaster* (Figure 12) and mice (Figure 13).

One consequence of the reduced mutations is that fewer cancer cells would be formed and would be in the equilibrium phase of the immunoediting process, and so there would be less chance of forming immune system-evading cancers. Another consequence of the DNA damage due to low-dose radiation exposures is that the damaged cells would upregulate retinoic acid early inducible proteins (RAE-1) and other ligands of the NKG2D receptor activating natural killer cells, which play an important role in eliminating tumor cells.

Other interventions that increase the immune system response such as reducing obesity, smoking cessation, fruit/vegetable diet, fasting, and so on—if they are applicable—should also be studied. The boosted immune system from all these interventions would eliminate the precancerous and cancerous cells more efficiently, reducing the number of cancer cells in the equilibrium phase undergoing Darwinian evolution. Hence, there would be less development of the immune system evading cancers using this approach to cancer prevention.

**Treatment of Cancer**

According to the immune suppression model of cancer, when the immune system response goes down due to aging, lifestyle, and so on, covert cancers can start growing and manifest as early-stage overt cancers. When such early-stage cancers are detected through traditional cancer screening methods or observed symptoms, a boosted immune system would likely be able to eliminate the cancers or bring them under control again, converting them back to covert cancers. Thus, a method
of treating early-stage cancers would be to boost the immune system, and this can be achieved, for example, with exercise, infection, and low-dose radiation. Even for late-stage cancers, enhancing the immune system with infection has resulted in complete remission of cancer. Hence, immune system boosting interventions should be tested in clinical trials for all stages of cancers.

Physical activity increases immune system response, and studies have indicated that physical activity improves survival in patients with cancer overall as well as for colorectal cancer, breast cancer, and prostate cancer, suggesting the study of exercise for treating cancers. A recent review has indicated that structured exercise may have a potential of reducing cancers in patients with early-stage cancer.

Another method of boosting the immune system is via infection. Postoperative infection in patients with osteosarcoma has been associated with improved survival supporting the concept that infection may be helpful in treating cancers. Spontaneous remission of cancer has been observed to be highly correlated with prior feverish infections, indicating that infection had a cancer therapeutic effect. The use of mixed bacteria vaccine for treating cancers was studied over a century ago by Coley and attained results comparable to results achieved with modern-day treatments. Hence, such a mixed bacteria vaccine should be studied for the treatment of cancer.

A third method of enhancing the immune system is through exposure to low-dose radiation. Repeated application of low-dose radiation to the whole body has been utilized for treating cancer in several clinical trials and has resulted in patient survival comparable to or better than chemotherapy and so has been recommended as a method of cancer treatment. Adjuvant whole-body or half-body low-dose radiation treatments interspersed between radiation therapy sessions resulted in better patient survival compared to radiation therapy alone.

In these studies, whole body dose of 10 or 15 cGy was given 15 or 10 times during 5 weeks, respectively, for a total dose of 1.5 Gy. Since there was concern regarding increased likelihood of leukemia when total dose of 2 Gy or more had been utilized for the treatments, clinical trials should be conducted with lower cumulative dose from the low-dose radiation treatments to determine if such treatments are effective in eliminating the cancers while reducing the chance for increased leukemias. The lower cumulative radiation dose may also be helpful in reducing the occurrence of thrombocytopenia sometimes observed following such treatments in the clinical trials.

These and other immune system boosting treatments should be tailored to the individual to achieve the most enhancement of the immune system. For example, if the person diagnosed with early-stage cancer had led a sedentary lifestyle, a change in lifestyle that includes vigorous exercise would likely boost the immune system. If the patient had already been exercising regularly when diagnosed with cancer, a more intense exercise regimen should be prescribed to boost the immune system to higher levels than earlier. A single method of boosting the immune system would not be sufficient for eliminating the cancers. Hence, clinical trials need to be conducted to study the efficacy of applying all the above methods (and any other additional methods of boosting the immune system) simultaneously or in sequence for treating cancers. For those cancers that do not respond to the immune system boosting treatments, traditional treatment methods such as surgery, radiation therapy, chemotherapy, immunotherapy, and so on would need to be applied.

**Discussion**

An alternative model of cancer, the immune suppression model of cancer, has been proposed here as the basis for dealing with cancer because the present approach to cancer, which is based on the invalid somatic mutation model of cancer, has not been successful in reducing the adverse impact of cancer, despite major advances in the field during the past several decades. The recommended approach to cancer screening, of identifying individuals with weakened immune system response through assays, needs to be tested in clinical trials to ascertain its validity. Considerable evidence supports the suggested approach of boosting the immune system using exercise, infection, and low-dose radiation to prevent and treat cancer. Other interventions that increase the immune system response such as reducing obesity, smoking cessation, fruit/vegetable diet, fasting, and so on—if they are applicable—should also be studied. By applying these interventions simultaneously or in sequence, we may be able to achieve a much higher reduction in cancer mortality rates than the reductions that individual interventions have achieved in the past. The immune system boosting interventions would eliminate cancerous/precancerous cells more efficiently and so would reduce Darwinian evolution of cancers that evade the immune system. There would also be very few adverse side effects from the suggested treatments. In summary, this changed paradigm of cancer screening, prevention,
and treatment based on the immune suppression model of cancer can result in a significant reduction of cancer incidence, cancer treatment adverse side effects, and cancer mortality rates, which have not been possible with the present approach that is based on the somatic mutation model of cancer.

**Conclusion**

Clinical trials are needed to validate the changed paradigm of cancer screening, prevention, and treatment based on the immune suppression model of cancer. Existing evidence indicates this approach would be successful in substantially reducing the adverse impact of cancer. Adoption of the proposed cancer paradigm can pay rich dividends in terms of significantly reduced cancer incidence and mortality rates while essentially eliminating the adverse side effects of present cancer treatments.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Eckhouse S, Lewison G, Sullivan R. Trends in the global funding and activity of cancer research. *Mol Oncol.* 2008;2(1):20-32.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000; 100(1):57-70.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144(5):646-674.
4. Timeline: Major Milestones Against Cancer. American Society of Clinical Oncology. 2013. http://www.cancerprogress.net/time line-major-milestones-against-cancer. Accessed August 1, 2016.
5. Hunter DJ, Reddy KS. Noncommunicable diseases. *N Engl J Med.* 2013;369(14):1336-1343.
6. Goldstein I, Madar S, Rotter V. Cancer research, a field on the verge of a paradigm shift? *Trends Mol Med.* 2012;18(6):299-303.
7. Diamandis EP, Bast RC Jr, Lopez-Otin C. Conquering cancer in our lifetime: new diagnostic and therapeutic trends. *Clin Chem.* 2013;59(1):1-3.
8. Hanahan D. Rethinking the war on cancer. *Lancet.* 2014; 383(9916):558-563.
9. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? *Bioessays.* 2004; 26(10):1097-1107.
10. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science.* 2015;347(6217):78-81.
11. Ettzioni R, Urban N, Ramsey S, et al. The case for early detection. *Nat Rev Cancer.* 2003;3(4):243-252.
12. Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. *CA Cancer J Clin.* 2015;65(1):30-54.
13. Lees BF, Erickson BK, Huh WK. Cervical cancer screening: evidence behind the guidelines. *Am J Obstet Gynecol.* 2016; 214(4):438-443.
14. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epi- demic”—screening and overdiagnosis. *N Engl J Med.* 2014; 371(19):1765-1767.
15. Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. *Cochrane Database Syst Rev.* 2013(6):CD001877.
16. Fuller MS, Lee CI, Elmore JG. Breast cancer screening: an evidence-based update. *Med Clin North Am.* 2015;99(3):451-468.
17. Kim EH, Andriole GL. Prostate-specific antigen-based screening: controversy and guidelines. *BMC Med.* 2015;13:61.
18. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. *Cancer Causes Control.* 2010;21(2):275-282.
19. Welch HG, Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst.* 2010;102(9):605-613.
20. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2012;157(2):120-134.
21. Pettit SD, Lipshultz SE, Cleeland CS, et al. Enhancing quality of life as a goal for anticancer therapeutics. *Sci Transl Med.* 2016; 8(344):344ed9.
22. Luqmani YA. Breast screening: an obsessive compulsive disorder. *Cancer Causes Control.* 2014;25(10):1423-1426.
23. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and over- treatment of prostate cancer. *Eur Urol.* 2014;65(6):1046-1055.
24. Donovan JL. Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/ monitoring. *J Natl Cancer Inst Monogr.* 2012;2012(45):191-196.
25. Xu J, Neale AV, Dailey RK, Eggly S, Schwartz KL. Patient perspective on watchful waiting/active surveillance for localized prostate cancer. *J Am Board Fam Med.* 2012;25(6):763-770.
26. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives”—and what we can do about it. *BMJ.* 2016;352:h6080.
27. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. *Natl Vital Stat Rep.* 2016;65(4):1-122.
28. AACR Cancer Progress Report 2012: American Association for Cancer Research. http://cancerprogressreport.org/2011/Documents/2011_ AACR_CPR_Text_8-03-12.pdf. Accessed August 1, 2016.
29. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? *Tob Control.* 2006;15(5):345-347.
30. Soto AM, Sonnenschein C. One hundred years of somatic mutation theory of carcinogenesis: is it time to switch? *Bioessays.* 2014;36(1):118-120.
31. Sonnenschein C, Soto AM. Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. *Mol Carcinog.* 2000;29(4):205-211.
32. DeGregori J. Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? *Onco- gene.* 2013;32(15):1869-1875.
33. Cancer Incidence by Age in the UK in 2011–2013. Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-Zero. Accessed June 22, 2016.

34. Inaida K, Hasegawa R, Kato T, et al. Clinicopathological analysis on cancers of autopsy cases in a geriatric hospital. Pathol Int. 1997;47(5):293-300.

35. Greaves M. Does everyone develop covert cancer? Nat Rev Cancr. 2014;14(4):209-210.

36. Martinezcorena I, Roshan A, Gerstung M, et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348(6237):880-886.

37. Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580-593.

38. National Toxicology Program. NTP toxicology and carcinogenesis studies of sodium azide (CAS: 26628-22-8) in F344 rats (gavage studies). Natl Toxicol Program Tech Rep Ser. 1991;389:1-165.

39. Maciak S, Michalak P. Cell size and cancer: a new solution to Peto’s paradox? Evol Appl. 2015;8(1):2-8.

40. Haas D, Ablin AR, Miller C, Zoger S, Matthy KK. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer. 1988;62(4):818-825.

41. Fogarty MC, Hughes CM, Burke G, et al. Exercise-induced lipid peroxidation: implications for deoxyribonucleic acid damage and systemic free radical generation. Environ Mol Mutagen. 2011;52(1):35-42.

42. Orsini N, Mantzoros CS, Wolk A. Association of physical activity and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2012;24(4):1098-1111.

43. Oliveira Cobucci RN, Saconato H, Lima PH, et al. Comparative incidence of cancer in HIV-AIDS patients and transplant recipients. Cancer Epidemiol. 2012;36(2):e69-e73.

44. Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada. JAMA Oncol. 2016;2(4):463-469.

45. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903-907.

46. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500.

47. Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014;5(197):1-8.

48. Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869-874.

49. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.

50. Wang H, Diepgen TL. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy. 2005;60(9):1098-111.

51. Turfkruyer M, Verhasselt V. Breast milk and its impact on maturation of the neonatal immune system. Curr Opin Infect Dis. 2015;28(3):199-206.

52. Amitay EL, Keinan-Boker L. Breastfeeding and childhood leukemia incidence: a meta-analysis and systematic review. JAMA Pediatr. 2015;169(6):e151025.

53. Woods JA, Keylock KT, Lowder T, et al. C exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. J Am Geriatr Soc. 2009;57(12):2183-2191.

54. Karbach J, Neumann A, Brand K, et al. Phase I clinical trial of mixed bacterial vaccine (Coley’s toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012;18(19):5449-5459.

55. Richardson MA, Ramirez T, Russell NC, Moyle LA. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med. 1999;5(3):42-47.

56. Liu SZ. Nonlinear dose–response relationship in the immune system following exposure to ionizing radiation: mechanisms and implications. Nonlinearity Biol Toxicol Med. 2003;1(1):71-92.

57. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Cancr. 2009;9(5):377-384.

58. Molina PE, Happef KI, Zhang P, Kolls JK, Nelson S. Focus on: alcohol and the immune system. Alcohol Res Health. 2010;33(1-2):97-108.

59. Ozasa K, Shimizu Y, Suyama A, et al. Studies of the mortality of atomic bomb survivors, report 14, 1950–2003: an overview of cancer and noncancer diseases. Radiat Res. 2012;177(3):229-243.

60. Nelson DE, Jarman DW, Rehm J, et al. Alcohol-attributable cancer deaths and years of potential life lost in the United States. Am J Public Health. 2013;103(4):641-648.

61. Yang G, Kong Q, Wang G, et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm. 2014;29(10):428-434.

62. Hwang SL, Guo HR, Hsieh WA, et al. Cancer risks in a population with prolonged low-dose-rate gamma-radiation exposure in radiocontaminated buildings, 1983–2002. Int J Radiat Biol. 2006;82(12):849-858.

63. Sponsler R, Cameron JR. Nuclear shipyard worker study 1980–1989: health effects in a cohort of shipyard workers in an area near Plutonium production area. Sci Total Environ. 1989;142(1-2):119-125.

64. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunity: tolerance, infection, and developmental regression. Annu Rev Immunol. 2004;22:329-360.

65. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.

66. Imaida K, Hasegawa R, Kato T, et al. Clinicopathological analysis on cancers of autopsy cases in a geriatric hospital. Pathol Int. 1997;47(5):293-300.

67. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.

68. Imaida K, Hasegawa R, Kato T, et al. Clinicopathological analysis on cancers of autopsy cases in a geriatric hospital. Pathol Int. 1997;47(5):293-300.
69. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116(9):1081-1093.

70. Centers for Disease Control and Prevention (CDC). Adult participation in aerobic and muscle-strengthening physical activities—United States, 2011. *MMWR Morb Mortal Wkly Rep*. 2013;62(17):326-330.

71. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U; Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. *Lancet*. 2012;380(9838):247-257.

72. Rudant J, Lightfoot T, Urayama KY, et al. Childhood acute lymphoblastic leukemia and indicators of early immune stimulation: a childhood leukemia international consortium study. *Am J Epidemiol*. 2015;181(8):549-562.

73. Kleef R, Jonas WB, Knogler W, Stenzinger W. Fever, cancer incidence and spontaneous remissions. *Neuroimmunomodulation*. 2001;9(2):55-64.

74. Feinendegen LE, Pollycove M, Neumann RD. Hormesis by low dose radiation effects: low-dose cancer risk modeling must recognize up-regulation of protection. In: Baum RP, ed. *Therapeutic Nuclear Medicine*. Heidelberg: Springer; 2014.

75. Koana T, Tsujimura H. A U-shaped dose–response relationship between x radiation and sex-linked recessive lethal mutation in male germ cells of Drosophila. *Radiat Res*. 2010;174(1):46-51.

76. Osipov AN, Buleeva G, Arkhangelskaya E, Klokov D. In vivo gamma-irradiation low dose threshold for suppression of DNA double strand breaks below the spontaneous level in mouse blood and spleen cells. *Mutat Res*. 2013;756(1-2):141-145.

77. Gasser S, Raulet DH. The DNA damage response arouses the immune system. *Cancer Res*. 2006;66(8):3959-3962.

78. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. *Proc Nutr Soc*. 2012;71(2):332-338.

79. Maijo M, Clements SJ, Ivory K, Nicoletti C, Carding SR. Nutrition, diet and immunosenescence. *Mech Ageing Dev*. 2014;136:137:116-128.

80. Cheng CW, Adams GB, Perin L, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. *Cell Stem Cell*. 2014;14(6):810-823.

81. Jessy T. Immunity over inability: the spontaneous regression of cancer. *J Nat Sci Biol Med*. 2011;2(1):43-49.

82. Lee IM, Wolin KY, Freeman SE, Sattelmair J, Sesso HD. Physical activity and survival after cancer diagnosis in men. *J Phys Act Health*. 2014;11(1):85-90.

83. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. *J Clin Oncol*. 2006;24(22):3527-3534.

84. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. *Med Oncol*. 2011;28(3):753-765.

85. Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS. Physical activity and survival after prostate cancer [published online January 7, 2016]. *Eur Urol*. pii: S0302-2838(15)01241-5.

86. Scott JM, Koelwyn GJ, Hornsby WE, et al. Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer. *Semin Oncol*. 2013;40(2):218-228.

87. Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? *Ann Surg Oncol*. 2007;14(10):2887-2895.

88. Bickels J, Kollender Y, Merinsky O, Meller I. Coley’s toxin: historical perspective. *Isr Med Assoc J*. 2002;4(6):471-472.

89. Wong S, Slavcev RA. Treating cancer with infection: a review on bacterial cancer therapy. *Lett Appl Microbiol*. 2015;61(2):107-112.

90. Yang G, Li W, Jiang H, et al. Low-dose radiation may be a novel approach to enhance the effectiveness of cancer therapeutics [published online November 15, 2016]. *Int J Cancer*. 139(10):2157-2168.

91. Cuttler JM, Pollycove M. Can cancer be treated with low doses of radiation? *J Am Phys Surg*. 2003;8(4):108-111.

92. Pollycove M. Radiobiological basis of low-dose irradiation in prevention and therapy of cancer. *Dose Response*. 2007;5(1):26-38.

93. Sakamoto K. Radiobiological basis for cancer therapy by total or half-body irradiation. *Nonlinearity Biol Toxicol Med*. 2004;2(4):293-316.

94. Travis LB, Weeks J, Curtis RE, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin’s lymphoma. *J Clin Oncol*. 1996;14(2):565-571.

95. Chaffey JT, Rosenthal DS, Moloney WC, Hellman S. Total body irradiation as treatment for lymphosarcoma. *Int J Radiat Oncol Biol Phys*. 1976;1(5-6):399-405.